Oscient Pharmaceuticals Corporation reported a working capital
deficit of US$11.37 million at Sept. 30, 2008, according to its
Registration Statement filed on Form S-1 with the U.S. Securities
and Exchange…
provides timely updates on public companies reporting a working capital deficit to the U.S. Securities and Exchange Commission. Companies with minimum total assets of USD $5 million are covered. Liquidity Alert highlights significant events affecting liquidity, cash flows, estimated capital expenditures, and capital raising efforts.